Adhera Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223042138 Filed on November 20, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.39K $32.00K
YoY Change -75.65% -57.89%
Cash & Equivalents $32.39K $32.00K
Short-Term Investments
Other Short-Term Assets $11.69K $47.00K
YoY Change -90.5% -60.83%
Inventory
Prepaid Expenses $11.69K $47.00K
Receivables
Other Receivables
Total Short-Term Assets $44.07K $79.00K
YoY Change -82.78% -59.69%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $44.07K $79.00K
Total Long-Term Assets $0.00 $0.00
Total Assets $44.07K $79.00K
YoY Change -82.78% -59.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.352M $2.397M
YoY Change 1.72% 3.81%
Accrued Expenses $5.546M $4.373M
YoY Change 37.24% 40.61%
Deferred Revenue $100.0K
YoY Change
Short-Term Debt $1.169M $1.252M
YoY Change 4.17% 26.98%
Long-Term Debt Due $9.660M $7.333M
YoY Change 40.62% 29.17%
Total Short-Term Liabilities $26.36M $22.27M
YoY Change 19.47% -12.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $26.36M $22.27M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $26.36M $22.27M
YoY Change 19.47% -12.0%
SHAREHOLDERS EQUITY
Retained Earnings -$60.00M -$55.80M
YoY Change 8.3% 5.25%
Common Stock $31.01K $19.00K
YoY Change 72.3% -81.37%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.000K $2.000K
YoY Change 0.0%
Treasury Stock Shares 5.594K shares
Shareholders Equity -$26.30M -$22.20M
YoY Change
Total Liabilities & Shareholders Equity $44.07K $79.00K
YoY Change -82.78% -59.69%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000737207
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Revenues
Revenues
usd
CY2022Q3 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2023Q3 us-gaap Loan Processing Fee
LoanProcessingFee
usd
CY2022Q3 us-gaap Loan Processing Fee
LoanProcessingFee
usd
us-gaap Loan Processing Fee
LoanProcessingFee
usd
CY2023Q3 ATRX Issuance Of Common Stock For Cashless Warrant Exercises
IssuanceOfCommonStockForCashlessWarrantExercises
usd
us-gaap Loan Processing Fee
LoanProcessingFee
usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
ATRX Purchase Of Treasury Stock
PurchaseOfTreasuryStock
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
ATRX Conversion Of Series E Preferred Stock To Common Stock
ConversionOfSeriesEPreferredStockToCommonStock
usd
ATRX Conversion Of Serie F Preferred Stock To Common Stock
ConversionOfSerieFPreferredStockToCommonStock
usd
CY2023Q3 ATRX Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
dei Document Type
DocumentType
10-Q
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3649428 shares
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-13789
dei Entity Registrant Name
EntityRegistrantName
ADHERA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2658569
dei Entity Address Address Line1
EntityAddressAddressLine1
8000 Innovation Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70820
dei City Area Code
CityAreaCode
(919)
dei Local Phone Number
LocalPhoneNumber
518-3748
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7220900 shares
CY2023Q3 us-gaap Cash
Cash
32388 usd
CY2022Q4 us-gaap Cash
Cash
31761 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11686 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
46750 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
44074 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
78511 usd
CY2023Q3 us-gaap Assets
Assets
44074 usd
CY2022Q4 us-gaap Assets
Assets
78511 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2351653 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2396716 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5545905 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4372366 usd
CY2023Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
578333 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
498453 usd
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
9660355 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7332978 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1168765 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1251696 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
100000 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6892612 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6386284 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
26359515 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22264061 usd
CY2023Q3 us-gaap Liabilities
Liabilities
26359515 usd
CY2022Q4 us-gaap Liabilities
Liabilities
22264061 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5168912 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5168912 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3160877 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3160877 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
31014 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18938 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33636179 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33547890 usd
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5594 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5594 shares
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
2000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59980637 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55750381 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-26315441 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22185550 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44074 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78511 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
83267 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
169166 usd
us-gaap Professional Fees
ProfessionalFees
339972 usd
us-gaap Professional Fees
ProfessionalFees
521861 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
143238 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
154161 usd
us-gaap Share Based Compensation
ShareBasedCompensation
429396 usd
us-gaap Share Based Compensation
ShareBasedCompensation
304161 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42992 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
224243 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
148153 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
430268 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
269497 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
547570 usd
us-gaap Operating Expenses
OperatingExpenses
917521 usd
us-gaap Operating Expenses
OperatingExpenses
1256290 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-269497 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-547570 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-917521 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1256290 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
359184 usd
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
317045 usd
us-gaap Interest Expense Other
InterestExpenseOther
1050830 usd
us-gaap Interest Expense Other
InterestExpenseOther
989288 usd
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
245839 usd
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
777082 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1245825 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1265419 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
12671 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
92068 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
87921 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
306707 usd
us-gaap Loan Processing Fee
LoanProcessingFee
809126 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2673966 usd
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-253723 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-214994 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1425494 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3266318 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1255782 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3232854 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-522506 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3535815 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1803352 usd
us-gaap Net Income Loss
NetIncomeLoss
-4150375 usd
us-gaap Net Income Loss
NetIncomeLoss
-1778796 usd
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26920 usd
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8706 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
79881 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
574706 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3562735 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1812058 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4230256 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2353502 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4303866 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3160877 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3649428 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2019953 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4303866 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3160877 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2019953 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22185550 usd
CY2023Q1 us-gaap Dividends
Dividends
26334 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-885839 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23092723 usd
CY2023Q2 us-gaap Dividends
Dividends
26627 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
60847 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
271279 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22787224 usd
CY2023Q3 us-gaap Dividends
Dividends
26920 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
34518 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3535815 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-26315441 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-25105618 usd
CY2022Q1 us-gaap Dividends
Dividends
364166 usd
CY2022Q1 ATRX Stock Issued During Period Value Conversion With Convertible Note
StockIssuedDuringPeriodValueConversionWithConvertibleNote
17980 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
27984 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-73730 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-25497550 usd
CY2022Q2 us-gaap Dividends
Dividends
201834 usd
CY2022Q2 ATRX Stock Issued During Period Value Issuance Of Common Stock With Term Loan
StockIssuedDuringPeriodValueIssuanceOfCommonStockWithTermLoan
11820 usd
CY2022Q2 ATRX Stock Issued During Period Value Conversion Of Series E Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesEPreferredStockForCommonStock
5056639 usd
CY2022Q2 ATRX Stock Issued During Period Value Conversion Of Series F Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesFPreferredStockForCommonStock
541259 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
98286 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-19993380 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-19993380 usd
CY2022Q3 us-gaap Dividends
Dividends
8706 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1803352 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1803352 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-21805438 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-21805438 usd
us-gaap Net Income Loss
NetIncomeLoss
-4150375 usd
us-gaap Net Income Loss
NetIncomeLoss
-1778796 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
87921 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
306707 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-214994 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1425494 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1245825 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1265419 usd
us-gaap Loan Processing Fee
LoanProcessingFee
809126 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-35064 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3555 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8739 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-38167 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1186871 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
931338 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
100000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-655155 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1355962 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
788900 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2000000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
200000 usd
ATRX Repayment Of Notes Payable And Convertible Notes Issuance Costs
RepaymentOfNotesPayableAndConvertibleNotesIssuanceCosts
42300 usd
ATRX Repayment Of Notes Payable And Convertible Notes Issuance Costs
RepaymentOfNotesPayableAndConvertibleNotesIssuanceCosts
327800 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
90818 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
456954 usd
ATRX Purchase Of Treasury Stock
PurchaseOfTreasuryStock
2000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
655782 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1413246 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
627 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
57284 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31761 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76104 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32388 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
133388 usd
us-gaap Interest Paid Net
InterestPaidNet
17513 usd
us-gaap Interest Paid Net
InterestPaidNet
117301 usd
ATRX Conversion Of Series E Preferred Stock To Common Stock
ConversionOfSeriesEPreferredStockToCommonStock
5056635 usd
ATRX Conversion Of Serie F Preferred Stock To Common Stock
ConversionOfSerieFPreferredStockToCommonStock
541258 usd
ATRX Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
406846 usd
ATRX Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
1342957 usd
us-gaap Stock Issued1
StockIssued1
72774 usd
us-gaap Stock Issued1
StockIssued1
9922 usd
ATRX Accrued Dividends
AccruedDividends
79881 usd
ATRX Accrued Dividends
AccruedDividends
574705 usd
CY2023Q3 us-gaap Cash
Cash
32000 usd
CY2023Q3 ATRX Working Capital
WorkingCapital
26300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4150375 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-655155 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-26300000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60000000.0 usd
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-20
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-20 reverse stock split
CY2023Q3 us-gaap Cash
Cash
32000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zRmG0LcrhAod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z5w4cVe2DBc8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6892612 usd
CY2023Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
6892612 usd
CY2022Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
6386284 usd
ATRX Initial Valuation Of Derivative Liabilities Included In Debt Discount
InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount
406846 usd
ATRX Initial Valuation Of Derivative Liabilities Included In Derivative Expense
InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense
564483 usd
ATRX Reclassification Of Derivative Liabilities To Gain On Debt Extinguishment
ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment
-115512 usd
ATRX Change In Fair Value Included In Derivative Expense Income
ChangeInFairValueIncludedInDerivativeExpenseIncome
-349489 usd
CY2023Q3 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
6892612 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z6UBvOMyCoBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_zwQsL7H1G6Ki">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made in the consolidated financial statements to conform to the current period presentation. Such reclassifications had no impact on the Company’ previously reported consolidated financial position or results of operations. Specifically, on the consolidated financial statements, all amounts are now reflected in whole dollars and all rounding to thousands has been eliminated. Additionally, on the consolidated statements of operations, professional fees and compensation expense has been reclassified from general and administrative expenses and are shown separately as part of operating expenses. Furthermore, for the nine months ended September 30, 2022, certain reclassifications were made on the consolidated statement of cash flows to conform to the current presentation. The reclassification on the 2022 consolidated statement of cash flow increased cash flows used in operations by approximately $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20220101__20220930__srt--RestatementAxis__srt--RestatementAdjustmentMember_zhWj56JqQYB" title="Increased cash flows used in operations">94,000 </span>and increased net cash provided by financing activities by $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInFinancingActivities_c20220101__20220930__srt--RestatementAxis__srt--RestatementAdjustmentMember_zx9DLLM7UVU7" title="Increased net cash provided by financing activities">94,000</span>.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
273925315 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7786089 shares
CY2023Q3 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
11686 usd
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
46750 usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
10054677 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
8041979 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
394322 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
709001 usd
CY2023Q3 us-gaap Loans Payable
LoansPayable
9660355 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
7332978 usd
CY2022Q4 us-gaap Debt Instrument Description
DebtInstrumentDescription
(i) the 12-month anniversary of the original issuance date of the Notes, or December 14, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
CY2023Q1 us-gaap Debt Instrument Description
DebtInstrumentDescription
(i) the 12-month anniversary of the original issuance date of the Notes, or January 18, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1168765 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1319024 usd
CY2022Q4 ATRX Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
67328 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1168765 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1251696 usd
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7138107 usd
CY2022Q1 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.16 pure
CY2022Q3 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.18 pure
CY2021Q4 ATRX Reclassification Of Additional Paid In Capital To Derivative Liability
ReclassificationOfAdditionalPaidInCapitalToDerivativeLiability
3462000 usd
CY2023Q3 ATRX Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2022Q4 ATRX Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
ATRX Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
22591 usd
ATRX Gains Losses On Extinguishment Of Debt Related To Removal Of Derivative Liabilities
GainsLossesOnExtinguishmentOfDebtRelatedToRemovalOfDerivativeLiabilities
110512 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
87921 usd
ATRX Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
22591 usd
ATRX Gains Losses On Extinguishment Of Debt Related To Removal Of Derivative Liabilities
GainsLossesOnExtinguishmentOfDebtRelatedToRemovalOfDerivativeLiabilities
110512 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
87921 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6785914 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
55317596 shares
us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
97481393 shares
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
4670301 shares
CY2023Q3 ATRX Cashless Exercise Of Warrant
CashlessExerciseOfWarrant
750000 shares
ATRX Share Based Compensation Arrangement By Share Based Payment Award Warrants Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExpirationsInPeriod
1520280 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
161984924 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
3400000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
19000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
100000 usd

Files In Submission

Name View Source Status
0001493152-23-042138-index-headers.html Edgar Link pending
0001493152-23-042138-index.html Edgar Link pending
0001493152-23-042138.txt Edgar Link pending
0001493152-23-042138-xbrl.zip Edgar Link pending
atrx-20230930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
atrx-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atrx-20230930_pre.xml Edgar Link unprocessable
atrx-20230930_cal.xml Edgar Link unprocessable
atrx-20230930_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending